Decoding cancer's camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockade.
Epithelial-to-mesenchymal transition
epithelial-mesenchymal plasticity
immune evasion
intrinsic and extrinsic mechanisms of resistance to immune checkpoint blockade
therapeutic opportunity
tumor immune microenvironment
Journal
Cancer drug resistance (Alhambra, Calif.)
ISSN: 2578-532X
Titre abrégé: Cancer Drug Resist
Pays: United States
ID NLM: 101738710
Informations de publication
Date de publication:
2020
2020
Historique:
received:
12
06
2020
revised:
11
09
2020
accepted:
17
09
2020
entrez:
18
5
2022
pubmed:
12
10
2020
medline:
12
10
2020
Statut:
epublish
Résumé
Epithelial-mesenchymal plasticity (EMP) of cancer cells contributes to cancer cell heterogeneity, and it is well established that EMP is a critical determinant of acquired resistance to cancer treatment modalities including radiation therapy, chemotherapy, and targeted therapies. Here, we aimed to explore how EMP contributes to cancer cell camouflage, allowing an ever-changing population of cancer cells to pass under the radar of our immune system and consequently compromise the effect of immune checkpoint blockade therapies. The ultimate clinical benefit of any combination regimen is evidenced by the sum of the drug-induced alterations observed in the variety of cellular populations composing the tumor immune microenvironment. The finely-tuned molecular crosstalk between cancer and immune cells remains to be fully elucidated, particularly for the spectrum of malignant cells along the epithelial to mesenchymal axis. High-dimensional single cell analyses of specimens collected in ongoing clinical studies is becoming a key contributor to our understanding of these interactions. This review will explore to what extent targeting EMP in combination with immune checkpoint inhibition represents a promising therapeutic avenue within the overarching strategy to reactivate a halting cancer-immunity cycle and establish a robust host immune response against cancer cells. Therapeutic strategies currently in clinical development will be discussed.
Identifiants
pubmed: 35582229
doi: 10.20517/cdr.2020.41
pmc: PMC8992561
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
832-853Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Rayford A is an industrial PhD candidate at University of Bergen co-funded by BerGenBio ASA and the Research Council of Norway’s industrial PhD scheme. Thiery JP is scientific founder and CSO of Biocheetah Pte Ltd Singapore and consultant/shareholder Biosyngen Pte Lte Limited and ACTgenomics Taipei Taiwan. Lorens JB is founder and shareholder of BerGenBio ASA. The remaining authors declared no conflicts of interest.
Références
Am J Pathol. 2009 May;174(5):1588-93
pubmed: 19342369
J Immunother Cancer. 2018 Jun 4;6(1):47
pubmed: 29866156
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
Nature. 2018 Feb 22;554(7693):544-548
pubmed: 29443960
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
Cancer Cell. 2013 Oct 14;24(4):466-80
pubmed: 24075834
Cancer Cell. 2012 Dec 11;22(6):709-24
pubmed: 23201163
Cell. 2008 May 16;133(4):704-15
pubmed: 18485877
Cells. 2019 Apr 05;8(4):
pubmed: 30959852
Cancer Res. 2018 Jul 15;78(14):3913-3925
pubmed: 29752261
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
EMBO Rep. 2018 Aug;19(8):
pubmed: 29907679
Nat Biotechnol. 2013 Sep;31(9):775-6
pubmed: 24022140
J Immunother Cancer. 2019 Nov 8;7(1):295
pubmed: 31703593
Prog Exp Tumor Res. 1970;13:1-27
pubmed: 4921480
Lancet Oncol. 2017 Jan;18(1):31-41
pubmed: 27932067
Lancet. 2016 Dec 3;388(10061):2796-2810
pubmed: 27345655
Crit Rev Immunol. 2014;34(2):91-102
pubmed: 24940910
Sci Signal. 2016 Oct 04;9(448):ra97
pubmed: 27703030
Cancer Res. 2015 Sep 15;75(18):3699-705
pubmed: 26206560
Front Oncol. 2015 Feb 13;5:31
pubmed: 25763355
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Science. 2015 Oct 9;350(6257):207-211
pubmed: 26359337
Appl Immunohistochem Mol Morphol. 2020 Mar;28(3):213-220
pubmed: 31058656
Br Med J. 1957 Apr 6;1(5022):779-86
pubmed: 13404306
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cancer Immunol Res. 2019 Nov;7(11):1789-1802
pubmed: 31488404
Nutr Rev. 1989 Jan;47(1):23-5
pubmed: 2649802
Nat Immunol. 2002 Nov;3(11):991-8
pubmed: 12407406
Front Med. 2018 Aug;12(4):361-373
pubmed: 30043221
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Cell. 2010 Apr 2;141(1):69-80
pubmed: 20371346
Acta Anat (Basel). 1995;154(1):8-20
pubmed: 8714286
Lung Cancer. 2020 Jan;139:1-8
pubmed: 31683225
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7
pubmed: 12218188
Nat Commun. 2014 Oct 28;5:5241
pubmed: 25348003
J Clin Oncol. 2015 Jun 10;33(17):1889-94
pubmed: 25667295
Cancer Cell. 2009 May 5;15(5):416-28
pubmed: 19411070
Nature. 2001 Apr 26;410(6832):1107-11
pubmed: 11323675
Mol Biol Cell. 2001 Jan;12(1):27-36
pubmed: 11160820
Immunol Rev. 2017 Nov;280(1):126-148
pubmed: 29027218
Oncotarget. 2015 Feb 10;6(4):2250-62
pubmed: 25544770
Nat Rev Clin Oncol. 2017 Oct;14(10):611-629
pubmed: 28397828
Br J Cancer. 2017 Feb 14;116(4):415-423
pubmed: 28072762
Cancer Discov. 2019 Aug;9(8):1124-1141
pubmed: 31186238
Cancer Discov. 2020 Feb;10(2):185-197
pubmed: 31974169
Clin Cancer Res. 2020 Jan 1;26(1):242-255
pubmed: 31585938
Nat Commun. 2018 Aug 29;9(1):3503
pubmed: 30158554
Cancer Discov. 2014 Jul;4(7):816-27
pubmed: 24771846
Cancer Res. 2005 Oct 15;65(20):9294-303
pubmed: 16230391
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Cancer Res. 2008 Feb 1;68(3):650-6
pubmed: 18245463
Cytokine Growth Factor Rev. 2017 Aug;36:67-77
pubmed: 28595838
Cancer Discov. 2018 Jun;8(6):730-749
pubmed: 29510987
J Exp Med. 2000 Oct 2;192(7):1027-34
pubmed: 11015443
Cancer Immunol Immunother. 2020 Feb;69(2):237-244
pubmed: 31664482
Lancet Oncol. 2017 Dec;18(12):e731-e741
pubmed: 29208439
J Immunother Cancer. 2019 Mar 4;7(1):62
pubmed: 30832732
Oncotarget. 2019 Apr 23;10(30):2887-2898
pubmed: 31080559
Cell. 2016 Mar 24;165(1):35-44
pubmed: 26997480
J Thorac Oncol. 2020 Jun;15(6):973-999
pubmed: 32018052
EMBO J. 1992 Nov;11(11):3887-95
pubmed: 1396582
Cancer Discov. 2017 Jul;7(7):659-660
pubmed: 28546286
Nat Commun. 2016 Feb 19;7:10690
pubmed: 26891683
Basic Clin Pharmacol Toxicol. 2015 Jan;116(1):9-18
pubmed: 25154903
Cells. 2019 May 15;8(5):
pubmed: 31096701
Oncotarget. 2016 Aug 9;7(32):52575-52583
pubmed: 27270649
Ir J Med Sci. 2017 Feb;186(1):57-62
pubmed: 27156054
Cells. 2019 Sep 14;8(9):
pubmed: 31540045
Clin Cancer Res. 2014 Feb 15;20(4):837-46
pubmed: 24323901
Thorac Cancer. 2019 Apr;10(4):775-781
pubmed: 30809973
Clin Cancer Res. 2020 Feb 15;26(4):970-977
pubmed: 31615933
Bull Cancer. 2011 Feb;98(2):E19-24
pubmed: 21339092
J Immunol. 2013 Dec 15;191(12):5802-6
pubmed: 24227785
Science. 2002 Apr 12;296(5566):301-5
pubmed: 11951032
Mol Cancer. 2019 Mar 30;18(1):70
pubmed: 30927908
Nature. 2018 Feb 22;554(7693):538-543
pubmed: 29443964
Cancer Res. 2017 Aug 1;77(15):3982-3989
pubmed: 28428275
Nat Rev Cancer. 2019 Dec;19(12):716-732
pubmed: 31666716
Annu Rev Immunol. 2013;31:51-72
pubmed: 23157435
Cell Mol Immunol. 2018 Aug;15(8):740-742
pubmed: 29400708
Annu Rev Cell Dev Biol. 2011;27:347-76
pubmed: 21740232
J Exp Med. 2014 May 5;211(5):781-90
pubmed: 24778419
Clin Cancer Res. 2019 May 15;25(10):3074-3083
pubmed: 30635339
J Cell Physiol. 2007 Nov;213(2):374-83
pubmed: 17680632
Immunity. 2017 Dec 19;47(6):1037-1050.e6
pubmed: 29221729
Nat Rev Clin Oncol. 2017 Nov;14(11):655-668
pubmed: 28653677
J Thorac Oncol. 2020 Jul;15(7):1210-1222
pubmed: 32173464
Cancer Cell. 2009 Mar 3;15(3):195-206
pubmed: 19249678
Int J Mol Sci. 2018 Oct 06;19(10):
pubmed: 30301213
Cancer Discov. 2017 Feb;7(2):188-201
pubmed: 27903500
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
PLoS Biol. 2011 Sep;9(9):e1001162
pubmed: 21980263
Immunity. 2017 Oct 17;47(4):789-802.e9
pubmed: 29045907
Nat Commun. 2014 Dec 15;5:5712
pubmed: 25502142
J Exp Med. 1995 Aug 1;182(2):459-65
pubmed: 7543139
Cell Stem Cell. 2019 Jan 3;24(1):65-78
pubmed: 30554963
J Exp Clin Cancer Res. 2019 Jan 7;38(1):6
pubmed: 30616627
Am J Cancer Res. 2019 Feb 01;9(2):212-218
pubmed: 30906623
J Clin Oncol. 2015 May 1;33(13):1430-7
pubmed: 25452452
Clin Orthop Relat Res. 1991 Jan;(262):3-11
pubmed: 1984929
Cell. 2007 Dec 14;131(6):1124-36
pubmed: 18083102
Nat Rev Cancer. 2002 Jun;2(6):442-54
pubmed: 12189386
Lancet. 2001 Feb 17;357(9255):539-45
pubmed: 11229684
Nature. 2018 Apr;556(7702):463-468
pubmed: 29670281
Nat Rev Drug Discov. 2019 Mar;18(3):197-218
pubmed: 30610226
Cell. 2009 Nov 25;139(5):871-90
pubmed: 19945376
Ann Oncol. 2019 Jan 1;30(1):44-56
pubmed: 30395155
Cancer Epidemiol Biomarkers Prev. 2019 Mar;28(3):546-554
pubmed: 30487133
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
Drug Des Devel Ther. 2015 Aug 10;9:4479-99
pubmed: 26309397
Oncoimmunology. 2015 Jan 7;3(12):e954463
pubmed: 25964858
Nat Med. 2016 Mar;22(3):262-9
pubmed: 26828195
Front Oncol. 2017 Aug 03;7:162
pubmed: 28824874
JAMA Oncol. 2017 Sep 14;3(9):e172411
pubmed: 28817753
Cancer Res. 2018 Oct 1;78(19):5631-5643
pubmed: 30104240
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
Int Immunopharmacol. 2018 Sep;62:29-39
pubmed: 29990692
Nat Rev Drug Discov. 2020 Jan;19(1):39-56
pubmed: 31601994
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Cancer Immunol Res. 2018 Oct;6(10):1122-1128
pubmed: 30279188
Cold Spring Harb Perspect Biol. 2012 Feb 01;4(2):
pubmed: 22300978
Trends Cancer. 2020 May;6(5):432-441
pubmed: 32348738
EMBO Mol Med. 2016 Oct 4;8(10):1143-1161
pubmed: 27596438
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32188703
Nat Med. 1999 Dec;5(12):1365-9
pubmed: 10581077
Eur J Med Chem. 2020 Jul 15;198:112354
pubmed: 32387837
Cell Stem Cell. 2017 Feb 2;20(2):233-246.e7
pubmed: 27989769
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Dermatol Ther. 2020 Mar;33(2):e13145
pubmed: 31664762
Novartis Found Symp. 2004;256:6-21; discussion 22-8, 49-52, 266-9
pubmed: 15027481
Nature. 2020 Apr;580(7802):257-262
pubmed: 32269339
Int J Biochem Mol Biol. 2012;3(2):117-36
pubmed: 22773954
Clin Cancer Res. 2017 Jun 15;23(12):2928-2933
pubmed: 28289089
Oncotarget. 2017 Jan 24;8(4):7175-7180
pubmed: 27764780
Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15449-54
pubmed: 20713713
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Science. 2016 Apr 8;352(6282):189-96
pubmed: 27124452
Trends Pharmacol Sci. 2014 Sep;35(9):479-88
pubmed: 25042456
Oncogene. 2017 Jan 26;36(4):439-445
pubmed: 27345407
Nat Rev Mol Cell Biol. 2020 Jun;21(6):341-352
pubmed: 32300252
Cell. 2012 Mar 2;148(5):1015-28
pubmed: 22385965
Sci Transl Med. 2020 Mar 25;12(536):
pubmed: 32213632
BMC Cancer. 2012 Jan 24;12:35
pubmed: 22273460
Autophagy. 2013 Jul;9(7):1104-6
pubmed: 23635487
Drugs. 2017 Aug;77(12):1369-1376
pubmed: 28643244
J Hematol Oncol. 2019 Nov 8;12(1):112
pubmed: 31703598
Oncoimmunology. 2017 Jan 17;6(2):e1271858
pubmed: 28344883
EMBO Mol Med. 2014 Sep 11;6(10):1279-93
pubmed: 25214461
Nat Rev Cancer. 2015 Jan;15(1):25-41
pubmed: 25533674
Front Cell Dev Biol. 2018 Apr 17;6:41
pubmed: 29719832
Cell. 2016 Jun 30;166(1):21-45
pubmed: 27368099
Nature. 2017 Jun 15;546(7658):431-435
pubmed: 28607484
Nature. 2015 Jul 9;523(7559):231-5
pubmed: 25970248
Cell. 2016 Oct 6;167(2):397-404.e9
pubmed: 27667683
Proc R Soc Med. 1910;3(Surg Sect):1-48
pubmed: 19974799
Oncotarget. 2017 Jan 24;8(4):5686-5691
pubmed: 27974686
J Clin Oncol. 2016 Oct 20;34(30):3672-3679
pubmed: 27601555
Oncogene. 2015 Apr 23;34(17):2261-71
pubmed: 24931170
Ann Oncol. 2015 Sep;26(9):1980-1987
pubmed: 26037795
Oncotarget. 2017 Dec 22;9(4):5058-5072
pubmed: 29435162
Mol Oncol. 2017 Jul;11(7):824-846
pubmed: 28614624
Nat Commun. 2016 Dec 23;7:13898
pubmed: 28008921
J Cell Biol. 1982 Oct;95(1):333-9
pubmed: 7142291
Science. 1996 Mar 22;271(5256):1734-6
pubmed: 8596936
Sci Signal. 2014 Sep 23;7(344):re8
pubmed: 25249658